Synergistic tumor vessel damage and tumor-eradicating function were observed after the coadministration of NGR-TNF with chemotherapeutics (doxorubicin, cisplatin, paclitaxel and gemcitabine) or other antitumor cytokines (INF-γ and endothelial-monocyte activating polypeptide II) [116–118]. The gene discussed is AIMP1; the disease is neoplasm.